In 1902, the scientist John Beard, at the time Professor at the University of Edinburgh, proposed that the pancreatic enzyme trypsin represents the body'¿¿s primary defense against cancer and would be useful as a cancer treatment. Despite his documentation and reputation '¿¿ he was nominated for the Nobel Prize in 1906 for his work in embryology '¿¿ most cancer experts rejected Beard'¿¿s thesis outright. However, not everyone dismissed Beard. A number of physicians employed pancreatic enzymes in the treatment of patients diagnosed with advanced cancer, often with remarkable results as reported in the scientific literature. These successes provoked a heated debate about the therapy in the first decade of the 20th century. In 1911 Beard published The Enzyme Treatment of Cancer and Its Scientific Basis, outlining his hypothesis, and the compelling results. Though published to some very positive reviews, the book was soon forgotten as the scientific community enthusiastically latched on to Madame Curie'¿¿s claim that radiation represented a simple non-toxic cure for cancer. It would be years before scientists realized radiation cured few cancers and was quite toxic '¿¿ Madame Curie herself died as a result of her exposure to uranium. Though Beard died in relative obscurity in 1924, contemporary evidence from molecular biology confirms many of his precepts.In 2010, nearly 100 years since publication of this book, it is time Beard'¿¿s work be reread. With billions of dollars spent in recent decades on cancer research with only slight success, Beard'¿¿s thesis warrants a thorough reconsideration.

In 1998, Nicholas Gonzalez, M.D. received National Cancer Institute approval for a clinical trial to evaluate his nutritional-enzyme approach in the treatment of patients with pancreatic cancer. Though Dr. Gonzalez hoped the venture would initiate an era of cooperation between conventional scientists and serious alternative researchers, problems plagued the study from its beginning. The design discouraged patient participation; conventional oncologists discouraged patients from joining and at times pressured those already admitted for nutritional therapy to change to more conventional treatment. Then in 2000 the NCI insisted that all patient selection decisions be turned over to the Principal Investigator, who as it turned out helped develop the chemotherapy protocol used as the control treatment.Repeatedly, the Principal Investigator approved patients for the nutritional treatment who did not meet the entry requirements, or who were too ill or uncommitted to follow the self-administered regimen. An evaluation by government scientists in early 2005 confirmed that so many patients had failed to follow the prescribed nutritional therapy that the data had little meaning. Despite such problems, without Dr. Gonzalez¿ knowledge the Principal Investigator published an article implying the study was properly run, patients complied fully and that the nutritional therapy had no effect.In response, Dr. Gonzalez, a former journalist, has written What Went Wrong, to bring the truth of this project to light, and show how bias, indifference, and at times incompetence undermined a promising research effort that, if properly run, might have ushered in a new direction in cancer treatment.

This monograph, completed in 1986, reports Dr. Gonzalez's investigation of the nutritional/enzyme cancer treatment developed by the controversial alternative practitioner Dr. William Donald Kelley. Dr. Gonzalez pursued this study, the first evaluation of an alternative cancer regimen by an outside academic researcher, under the direction of Robert A Good, Ph.D., M.D., considered to be the "founder of modern immunology" and for ten years President of Sloan-Kettering. Although never previously published, this monograph has been generating interest in the alternative and conventional medical world for over two decades.The book documents Dr. Gonzalez's in-depth analysis of Dr. Kelley's theories and practice, and demonstrates the potential value of this approach against even the most aggressive of cancers. The author includes 50 representative case histories of patients diagnosed with a variety of poor prognosis or terminal cancer who did well under Dr. Kelley's care, with copies of the actual relevant medical records. The results of Dr. Gonzalez's investigation have been discussed before a Congressional committee, on national TV, and in print media. This pioneering book is now available to all those with an interest in cancer in general, the enzyme treatment cancer in particular, alternative medicine, and Dr. Kelley.

pt.1 The science of cancer therapy --pt.2. The politics of cancer therapy.

Historian James. S. Olson has prepared a comprehensive, annotated bibliography of the history of cancer. The emphasis of this work is not so much on the medical aspects of cancer as it is on the historical documentation of the disease: its etiology, pathology, epidemiology, forms and manifestations, and the men and women who have distinguished themselves in the study and treatment of the disease. The book opens with a section devoted to the historical background of our knowledge of cancer and important medical/nonmedical personalities. The next section deals with the etiology of cancer--its genesis, epidemiology, pathology, and research and control. The largest part of the bibliography is devoted to the individual malignant diseases. Olson concludes with sections on the diagnosis and treatment of cancer, clinical services, and cancer institutions. The citations include books, articles from scholarly and general periodicals, medical and government publications, and primary and secondary sources. The annotations are descriptive. An important contribution to the study of medical history, Olson's bibliography will be of interest to scholars, students and those involved in the medical and scientific study of cancer.

Molecular Genetic Pathology, Second Edition presents up-to-date material containing fundamental information relevant to the clinical practice of molecular genetic pathology. Fully updated in each area and expanded to include identification of new infectious agents (H1N1), new diagnostic biomarkers and biomarkers for targeted cancer therapy. This edition is also expanded to include the many new technologies that have become available in the past few years such as microarray (AmpliChip) and high throughput deep sequencing, which will certainly change the clinical practice of molecular genetic pathology. Part I examines the clinical aspects of molecular biology and technology, genomics. Poharmacogenomics and proteomics, while Part II covers the clinically relevant information of medical genetics, hematology, transfusion medicine, oncology, and forensic pathology. Supplemented with many useful figures and presented in a helpful bullet-point format, Molecular Genetic Pathology, Second Edition provides a unique reference for practicing pathologists, oncologists, internists, and medical genetisists. Furthermore, a book with concise overview of the field and highlights of clinical applications will certainly help those trainees, including pathology residents, genetics residents, molecular pathology fellows, internists, hematology/oncology fellows, and medical technologists in preparing for their board examination/certification.

An overview of the current systems biology-based knowledge and the experimental approaches for deciphering the biological basis of cancer.

Comprehensive and practice-oriented, the fully updated 3rd Edition of this easy-to-use text covers the full range of obstetric and gynecologic pathology, including information on treatment and patient management. Written largely by the pathology and clinical faculty at Harvard's Brigham and Women's Hospital, it covers the most up-to-date information available in the field, including molecular genetics and diagnostics. Drs. Christopher P. Crum and Marisa R. Nucci are joined by new editors Scott R. Granter, Brooke E. Howitt, Mana M. Parast, and Theonia K. Boyd, to provide complete, beautifully illustrated coverage of both neoplastic and non-neoplastic disorders of the female genital system, ideal for improving pathological diagnosis. - Provides distinct diagnostic/differential diagnostic criteria for any potential obstetric/gynecologic specimen encountered in practice. - Features more than 2,250 full-color images, key points at the end of each chapter, and an appendix with commonly used ICD-10 codes - Covers topics not often found in gynecologic pathology textbooks, such as vulvodynia, and diseases of the anus. - Approaches topics from a practice-oriented point of view, beginning with clinical presentation and progressing through histopathology, differential diagnosis, and treatment for each disorder. - Emphasizes new practice issues and their biologic basis including approaches to vulvar, cervical and endometrial precursors as well as the underpinnings of cervical, endometrial and ovarian cancer. - A comprehensive look at mesenchymal neoplasia, including not only lower genital tract and uterus but also the retroperitoneum. - Expert ConsultTM eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.